Your browser doesn't support javascript.
loading
Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study.
Reijers, Sophie J M; Davies, Emma; Grünhagen, Dirk J; Fiore, Marco; Honore, Charles; Rastrelli, Marco; Vassos, Nikolaos; Podleska, Lars E; Niethard, Maya; Jakob, Jens; Perhavec, Andraz; Duarte, Carlos; González, Felipe; Deroose, Jan P; Stas, Marguerite; Boecxstaens, Veerle; Schrage, Yvonne; Snow, Hayden; Algarra, Salvador Martín; Said, Hector Martinez; Garcia-Ortega, Dorian Yarih; Martin, Karla; Mattsson, Jan; Djafarrian, Reza; Di Lorenzo, Giorgia; Colombo, Chiara; Gronchi, Alessandro; Matter, Maurice; Verhoef, Cornelis; Olofsson Bagge, Roger; Hohenberger, Peter; Hayes, Andrew J; van Houdt, Winan J.
Afiliação
  • Reijers SJM; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: s.reijers@nki.nl.
  • Davies E; Department of Surgical Oncology, Royal Marsden Hospital, 203 Fulham Rd., SW3 6JJ London, UK. Electronic address: emma.davies@icr.ac.uk.
  • Grünhagen DJ; Department of Surgical Oncology, Erasmus Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands. Electronic address: d.grunhagen@erasmusmc.nl.
  • Fiore M; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy. Electronic address: marco.fiore@istitutotumori.mi.it.
  • Honore C; Department of Surgical Oncology, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France. Electronic address: charles.honore@gustaveroussy.fr.
  • Rastrelli M; Department of Surgery Oncology and Gastroenterology, University of Padova, Via VIII Febbraio, 2, 35122 Padua, Italy; Department of Surgical Oncology, Istituto Oncologico Veneto (IOV), Via Gattamelata, 64, 35128 Padua, Italy. Electronic address: marco.rastrelli@iov.veneto.it.
  • Vassos N; Division of Surgical Oncology, Mannheim University Medical Center, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. Electronic address: nikolaos.vassos@umm.de.
  • Podleska LE; Department of Orthopaedic Oncology and Soft Tissue Sarcoma, Essen University Hospital, Hufelandstraße 55, 45147 Essen, Germany. Electronic address: lars-eric.podleska@uk-essen.de.
  • Niethard M; Department of Surgical Oncology, Helios Klinikum Berlin-Buch, Schwanebecker Ch 50, 13125 Berlin, Germany; Department of Orthopedic Surgery, University Medicine Greifswald, Fleischmannstraße 6, 17489 Greifswald, Germany. Electronic address: maya.niethard@helios-gesundheit.de.
  • Jakob J; Department of Orthopaedic Oncology and Soft Tissue Sarcoma, Essen University Hospital, Hufelandstraße 55, 45147 Essen, Germany. Electronic address: jens.jakob@med.uni-goettingen.de.
  • Perhavec A; Department of Surgical Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia. Electronic address: aperhavec@onko-i.si.
  • Duarte C; Department of Surgical Oncology, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogota, Colombia. Electronic address: duarte10.carlos@gmail.com.
  • González F; Department of Surgical Oncology, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogota, Colombia. Electronic address: felipeo.gonzalez@gmail.com.
  • Deroose JP; Department of Surgical Oncology, Martini Ziekenhuis, Van Swietenplein 1, 9728 NT Groningen, the Netherlands. Electronic address: j.deroose@mhz.nl.
  • Stas M; Department of Surgical Oncology, Universitair Ziekenhuis Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: marguerite.stas@uzleuven.be.
  • Boecxstaens V; Department of Surgical Oncology, Universitair Ziekenhuis Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: veerle.boecxstaens@uzleuven.be.
  • Schrage Y; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: y.schrage@nki.nl.
  • Snow H; Department of Surgical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000. Australia. Electronic address: hayden.snow@petermac.org.
  • Algarra SM; Department of Medical Oncology, Clínica Universidad de Navarra, Av. de Pío XII, 36, 31008 Pamplona, Spain. Electronic address: smalgarra@unav.es.
  • Said HM; Department of Surgical Oncology, National Cancer Institute Mexico, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, 14080 Mexico City, Mexico. Electronic address: mtzsaid@hotmail.com.
  • Garcia-Ortega DY; Department of Surgical Oncology, National Cancer Institute Mexico, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, 14080 Mexico City, Mexico. Electronic address: dr.dorian.garcia.ortega@gmail.com.
  • Martin K; Department of Surgical Oncology, National Cancer Institute Mexico, Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, 14080 Mexico City, Mexico. Electronic address: karlamartin1@gmail.com.
  • Mattsson J; Department of Surgery, Sahlgrenska University Hospital, Blå stråket 5, 413 45 Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Medicinaregatan 3, 413 90 Gothenburg, Sweden. Electronic address: jan.e.mattsson@vgregion.se.
  • Djafarrian R; Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland. Electronic address: Reza.Djafarrian@chuv.ch.
  • Di Lorenzo G; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy. Electronic address: g.dilorenzo9@campus.unimib.it.
  • Colombo C; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy. Electronic address: chiara.colombo@institutotumori.mi.it.
  • Gronchi A; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milan, Italy. Electronic address: alessandro.gronchi@istitutotumori.mi.it.
  • Matter M; Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland. Electronic address: maurice.matter@chuv.ch.
  • Verhoef C; Department of Surgical Oncology, Erasmus Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands. Electronic address: c.verhoef@erasmusmc.nl.
  • Olofsson Bagge R; Department of Surgery, Sahlgrenska University Hospital, Blå stråket 5, 413 45 Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Medicinaregatan 3, 413 90 Gothenburg, Sweden. Electronic address: roger.olofsson.bagge@gu.se.
  • Hohenberger P; Division of Surgical Oncology, Mannheim University Medical Center, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. Electronic address: peter.hohenberger@umm.de.
  • Hayes AJ; Department of Surgical Oncology, Royal Marsden Hospital, 203 Fulham Rd., SW3 6JJ London, UK. Electronic address: andrew.hayes@rmh.nhs.uk.
  • van Houdt WJ; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: w.v.houdt@nk.nl.
Eur J Cancer ; 190: 112949, 2023 09.
Article em En | MEDLINE | ID: mdl-37453241
ABSTRACT

OBJECTIVE:

The aim of this study was to investigate the response rates of different extremity soft-tissue sarcoma subtypes (eSTS) after isolated limb perfusion (ILP), based on an international multi-centre study. MATERIALS AND

METHODS:

The retrospective cohort comprised eSTS patients from 17 specialised ILP centres that underwent melphalan-based ILP, with or without recombinant human tumour necrosis factor (rhTNFα) (TM-ILP and M-ILP, respectively). Response was measured on imaging (magnetic resonance imaging) and/or clinical response, for which M-ILPs were excluded.

RESULTS:

A total of 1109 eSTS patients were included. The three most common histological subtypes were undifferentiated pleomorphic sarcoma (17%, n = 184), synovial sarcoma (16%, n = 175) and myxofibrosarcoma (8%, n = 87). rhTNFα was used in 93% (TM-ILP) and resulted in a significantly better overall response rate (ORR, p = 0.031) and complete responses (CR, p < 0.001) in comparison to M-ILP, without significant differences among histological subgroups. The ORR of TM-ILP was 68%, including 17% CR. Also, 80% showed progressive disease. Significantly higher response rates were shown for Kaposi sarcoma (KS) with 42% CR and 96% ORR (both p < 0.001), and significantly higher CR rates for angiosarcoma (AS, 45%, p < 0.001) and clear cell sarcoma (CCS, 31%, p = 0.049). ILP was followed by resection ≤ 6 months in 80% of the patients. The overall limb salvage rate was 88%, without significant differences among histological subgroups, but was significantly higher for ILP responders compared to non-responders (93% versus 76%, p < 0.001).

CONCLUSION:

ILP resulted in high response and LRS among all eSTS subtypes, however, with significant differences between subtypes with most promising results for KS, AS and CCS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Sarcoma de Kaposi / Neoplasias de Tecidos Moles Tipo de estudo: Observational_studies Limite: Adult / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Sarcoma de Kaposi / Neoplasias de Tecidos Moles Tipo de estudo: Observational_studies Limite: Adult / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article